Castleview Partners LLC Purchases 11,504 Shares of Bristol Myers Squibb Company $BMY

Castleview Partners LLC increased its position in Bristol Myers Squibb Company (NYSE:BMY) by 15.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 85,542 shares of the biopharmaceutical company’s stock after purchasing an additional 11,504 shares during the period. Bristol Myers Squibb accounts for about 2.3% of Castleview Partners LLC’s holdings, making the stock its 6th biggest holding. Castleview Partners LLC’s holdings in Bristol Myers Squibb were worth $4,614,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in BMY. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $25,000. Harbor Capital Advisors Inc. increased its holdings in shares of Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 313 shares during the period. Beacon Financial Strategies CORP purchased a new stake in Bristol Myers Squibb in the 4th quarter valued at $38,000. KERR FINANCIAL PLANNING Corp acquired a new stake in Bristol Myers Squibb during the 3rd quarter worth $35,000. Finally, JPL Wealth Management LLC acquired a new stake in Bristol Myers Squibb during the 3rd quarter worth $36,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Up 2.7%

BMY stock opened at $58.94 on Thursday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The stock has a market capitalization of $120.02 billion, a PE ratio of 17.08, a price-to-earnings-growth ratio of 0.16 and a beta of 0.26. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The company has a fifty day moving average of $58.69 and a 200-day moving average of $52.06.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company’s revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Analyst Ratings Changes

A number of research analysts have commented on the stock. UBS Group restated a “buy” rating and issued a $70.00 price objective on shares of Bristol Myers Squibb in a research note on Friday, March 6th. The Goldman Sachs Group reiterated a “neutral” rating and set a $57.00 target price (up from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Scotiabank reissued a “sector perform” rating and set a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Truist Financial set a $65.00 price target on Bristol Myers Squibb in a research report on Wednesday, December 3rd. Finally, Citigroup increased their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Nine equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $61.41.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.